- Home
- IMMX vs ACET Comparison
IMMX vs ACET Comparison
Compare IMMX & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- ACET
- Stock Information
- Founded
- IMMX 2014
- ACET 1947
- Country
- IMMX United States
- ACET United States
- Employees
- IMMX 21
- ACET N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- ACET Health Care
- Exchange
- IMMX Nasdaq
- ACET Nasdaq
- Market Cap
- IMMX 54.9M
- ACET 55.1M
- IPO Year
- IMMX 2021
- ACET N/A
- Fundamental
- Price
- IMMX $2.34
- ACET $0.72
- Analyst Decision
- IMMX Strong Buy
- ACET Buy
- Analyst Count
- IMMX 1
- ACET 6
- Target Price
- IMMX $7.00
- ACET $6.00
- AVG Volume (30 Days)
- IMMX 360.1K
- ACET 764.4K
- Earning Date
- IMMX 06-10-2025
- ACET 05-06-2025
- Dividend Yield
- IMMX N/A
- ACET N/A
- EPS Growth
- IMMX N/A
- ACET N/A
- EPS
- IMMX N/A
- ACET N/A
- Revenue
- IMMX N/A
- ACET N/A
- Revenue This Year
- IMMX N/A
- ACET N/A
- Revenue Next Year
- IMMX N/A
- ACET N/A
- P/E Ratio
- IMMX N/A
- ACET N/A
- Revenue Growth
- IMMX N/A
- ACET N/A
- 52 Week Low
- IMMX $1.26
- ACET $0.45
- 52 Week High
- IMMX $2.71
- ACET $1.70
- Technical
- Relative Strength Index (RSI)
- IMMX 61.49
- ACET 53.94
- Support Level
- IMMX $1.89
- ACET $0.64
- Resistance Level
- IMMX $2.50
- ACET $0.72
- Average True Range (ATR)
- IMMX 0.17
- ACET 0.06
- MACD
- IMMX 0.00
- ACET 0.01
- Stochastic Oscillator
- IMMX 73.77
- ACET 60.07
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.